GLP1-RA use, but not SGLT2-I or DPP4-I, appears to decrease non-fatal strokes in diabetic people at risk of CKD or CVD compared with those diabetics without a CKD- or CVD-related risk. This evidence concerns the gene GCG and chronic kidney disease.